Vertex Pharmaceuticals

Vertex completes phase II epilepsy study

Thursday, March 17, 2011 01:38 PM

Cambridge, Mass.-based Vertex Pharmaceuticals said results from a phase II study of VX-765 in patients with treatment-resistant epilepsy showed it met the primary endpoint of safety and tolerability. Results showed a similar safety profile for VX-765 as compared to placebo. Secondary endpoints and additional analyses evaluated the clinical activity of VX-765, and results support the initiation of a larger and longer-duration phase IIb study of VX-765 in people with treatment-resistant epilepsy. Vertex expects to begin this trial as early as the fourth quarter of 2011.

More... »


Vertex phase III study showed improvements in lung function

Monday, March 7, 2011 07:54 AM

Vertex Pharmaceuticals announced positive results from the phase III STRIVE study of VX-770, an oral medicine that targets the defective protein that causes cystic fibrosis (CF). STRIVE was designed to evaluate people with a mutation in the CF gene known as G551D. This study showed profound improvements in lung function through week 24 and sustained through week 48 among those who received VX-770 (n=83) compared to those treated with placebo (n=78). Improvements in all key secondary endpoints were also observed through week 48 among those who received VX-770.

More... »



CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.